All In Biotech

Drug Trial Radar · NCT06891417

Phase 1 Study of Chlamydia Trachomatis mRNA Vaccine in Adults.

A Phase 1, Randomized, Placebo-controlled, Multi-arm, Study to Evaluate the Safety of a Chlamydia Trachomatis mRNA Vaccine Candidate in Adults

Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

Mar 27, 2025

Primary completion

Nov 3, 2027

Study completion Nov 3, 2027

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Mar 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, care provider, investigator)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 44 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety of two doses (Dose 1 and Dose 2) of Chlamydia mRNA Vaccine candidate in adult participants aged 18 to 29 years (Chlamydia trachomatis seronegative) or 18 to 44 years (Chlamydia trachomatis seropositive). There will also be an assessment to potentially obtain an early immunogenicity signal of the Chlamydia mRNA vaccine candidate. This study will consist of 2 Cohorts assessing the safety of the two different doses: Cohort A (Dose 1 or placebo) and Cohort B (Dose 2 or placebo). All participants will be followed up to 12 months after the last study intervention administration. Thus, the expected duration of the participant's involvement will be 18 months.

Conditions

  • Chlamydia Trachomatis Immunization

Interventions

  • Chlamydia mRNA VaccineBiological

    Pharmaceutical Form: Suspension for injection Route of Administration: Intramuscular injection

  • PlaceboOther

    Pharmaceutical Form: Solution for injection Route of Administration: Intramuscular injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Presence of immediate unsolicited systemic adverse events (AEs)Time frame: Within 30 minutes after each vaccine injection
  2. Presence of solicited injection site and systemic reactionsTime frame: Up to 8 days, including the day of each vaccine injection
  3. Presence of unsolicited AEsTime frame: Up to 28 days after each vaccine injection.
  4. Presence of medically attended adverse events (MAAEs)Time frame: Up to 6 months after last vaccine injection
  5. Presence of all serious AEs (SAEs) and all adverse events of special interest (AESIs)Time frame: Up to 12 months after last vaccine injections
  6. Presence of related SAEs, and fatal SAEsTime frame: Throughout the study, appriximatley 18 months
  7. Presence of out-of-range biological test results (Sentinel Cohort and Safety Subset of Main Cohort)Time frame: Up to 8 days, including the day of each vaccine injection

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Investigational Site Number : 0360002

    Bruce, Australian Capital Territory, Australia · Recruiting

  • Investigational Site Number : 0360006

    Maroubra, New South Wales, Australia · Recruiting

  • Investigational Site Number : 0360005

    Sydney, New South Wales, Australia · Recruiting

  • Investigational Site Number : 0360001

    Albion, Queensland, Australia · Recruiting

  • Investigational Site Number : 0360004

    Morayfield, Queensland, Australia · Recruiting

  • Investigational Site Number : 0360003

    Southport, Queensland, Australia · Recruiting

  • Investigational Site Number : 0360010

    Melbourne, Victoria, Australia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.